Metronomic chemotherapy and cemiplimab in recurrent/metastatic HNSCC

Marcelo Bonomi, MD, The Ohio State University, Columbus, OH, discusses a Phase II Trial (NCT04862650) of low-dose weekly metronomic carboplatin and paclitaxel with cemiplimab for first-line treatment of recurrent or metastatic head and neck squamous cell cancer (HNSCC). The regimen showed meaningful clinical activity and a manageable toxicity profile, supporting its potential as a more tolerable immunochemotherapy option for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.